A multinational team analysing four TrialNet trials reports that children under eight years progressing rapidly to clinical type 1 diabetes show a paradoxically higher insulin

A novel [13C9,15N1]-glucagon tracer study in 12 healthy individuals undergoing multi-rate clamp visits demonstrates that glucose, not insulin, appears to be the main regulator of

A post-hoc analysis of the SELECT trial examines obstructive sleep apnea (OSA) outcomes in adults with established cardiovascular disease and obesity treated with semaglutide 2.4

A Diabetes Prevention Program Outcomes Study (DPPOS) analysis examines the association of randomization to metformin with prevalent cognitive impairment syndromes, addressing the long-standing question of

A pooled analysis of the SELECT, FLOW, and SOUL Phase 3 outcomes trials demonstrates that semaglutide reduces COVID-19-related complications and all-cause death, providing the first

A study reports that urinary post-translationally modified fetuin-A predicts renal outcomes independent of albuminuria and eGFR in type 2 diabetes, characterising a novel renal biomarker

An AdventHealth team reports that plasma-derived extracellular vesicle (EV) proteomics can distinguish partial clinical remission (PCR) in new-onset type 1 diabetes, pointing to a circulating

A study compares individualized care pathways against usual care for reducing prediabetes-to-diabetes conversion rates, addressing whether tailored, multi-dimensional intervention strategies deliver superior outcomes compared with

A dashboard-driven methodology for phenotyping high-utilization risk in pediatric type 1 diabetes provides a practical, deployable framework for identifying patients likely to require elevated healthcare

A study reports that high-dose semaglutide is associated with preservation of kidney function in people living with obesity without diabetes, extending the renal-protective evidence base